RxDoctor Payments Data

Pamela Blake, MD

Neurology · Washington, DCNPI 1548268691

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 67.3% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $6,842 and has fallen 77.7% since, to $1,523 in 2025.

$12,275in general payments, 2019–2025

Across 217 payments — averaging $56.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Teva Pharmaceuticals USA, Inc.$958
  • Tonix Medicines, Inc.$536
  • Lilly USA, LLC$517
  • Amgen$361
  • Lundbeck LLC$330
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$4,72538%
  • Speaking & faculty fees$5004%
  • Travel & lodging$9538%
  • Food & beverage$6,09750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,275 in reported general payments places this provider in the 75th percentile of 113 neurology providers in District of Columbia.

See all neurology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$129,632
Medicare patients
119
Services billed
15,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina64$108,238
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen144$2,616
Sumatriptan Succinate22$1,354
Morphine Sulfate ErMorphine Sulfate25$430
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$358
Naratriptan Hcl13$225
Lorazepam12$59
Promethazine Hcl17$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$8,259$108,23864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 113 neurology providers in District of Columbia.

Other neurology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →